Cancer Medicine, Volume 15, Issue 2, February 2026.ABSTRACT Aim Integration of locoregional treatments (LRTs) with atezolizumab plus bevacizumab (atezo/bev) has improved treatment outcomes, enabling an increasing number of patients with unresectable hepatocellular carcinoma (HCC) to achieve a complete response (CR). A comprehensive analysis of recurrence following CR may provide insights into prognosis.
Tasuku Nakabori +11 more
wiley +1 more source
Cancer, Volume 132, Issue 3, 1 February 2026.ABSTRACT Background While immune checkpoint inhibitors (ICIs) have shown significant efficacy, a common side effect is cutaneous immune‐related adverse events (irAEs). This study focuses on exploring the association between specific human leukocyte antigen (HLA) alleles and the development of cutaneous irAEs in melanoma patients undergoing ICI ...
Mckenzie DiLeo +12 more
wiley +1 more source
Efficacy and safety analysis of atezolizumab continuation beyond progression in extensive-stage small cell lung cancer [PDF]
Wenhao Shi +14 more
openalex +1 more source
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial [PDF]
, 2022 Samuel A. Funt +38 more
openalex +1 more source
Minimal residual disease in solid tumors: Clinical applications and future directions
Cancer, Volume 132, Issue 3, 1 February 2026.Abstract Minimal residual disease (MRD) refers to the presence of residual cancer cells or tumor‐derived fragments that persist after treatment and remain undetectable by conventional imaging or protein‐based assays. Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for MRD detection.
Theresa Abdo +8 more
wiley +1 more source
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study [PDF]
, 2022 Magali Rebucci-Peixoto +19 more
openalex +1 more source
MedComm, Volume 7, Issue 2, February 2026.Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao +8 more
wiley +1 more source
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM [PDF]
, 2023 Sandy W. Wong +10 more
openalex +1 more source
Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors
Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.ABSTRACT G protein‐coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody‐based therapies. This review offers an overview of the therapeutic GPCR‐antibody target landscape and examines the diversity ...
Catherine J. Hutchings +6 more
wiley +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.ABSTRACT Cachexia is a metabolic condition that accelerates the clearance of monoclonal antibodies in cancer patients and is a known mechanism causing time‐dependent clearance. Successful anticancer treatment often ameliorates symptoms of cachexia, reducing the drug clearance over time especially in patients who respond. Serum albumin level is a common
Jeffrey R. Proctor, Harvey Wong
wiley +1 more source